Literature DB >> 12576184

D2 antagonist-induced c-fos in an identified subpopulation of globus pallidus neurons by a direct intrapallidal action.

Lauren M Billings1, John F Marshall.   

Abstract

Much research now supports the view that the dopaminergic innervation of the globus pallidus external segment (GP) influences basal ganglia information processing via pallidal dopamine (DA) D2, D3, and possibly D1 receptors. Systemic DA agonists, or systemic or intrapallidal dopamine D2-class antagonist administration, can induce immediate early gene expression (IEG) in the rat GP. In view of the distinct chemical phenotypes and axonal projections of the GP neurons, it is important to characterize the population(s) of pallidal neurons responding to local DA manipulations. Parvalbumin (PV) immunostaining was used to identify one of the two principal GP neuron populations. Awake, behaving rats received intrapallidal infusions of the dopamine D2 antagonist sulpiride (50 or 100 ng), the D1-class antagonist SCH-23390 (100 ng), the D2-class agonist quinpirole (500 ng), the GABA(A) antagonist picrotoxin (0.25, 0.5 or 1 microg) or bicuculline (20 ng), the GABA(A) agonist muscimol (15 ng) or vehicle. Intrapallidal GABA manipulations were used to assess the likelihood that the effects of the DAergic drugs on Fos induction occurred secondarily to altering intrapallidal GABA release. Using Fos and PV double immunolabeling procedures, we found that several treatments induced GP Fos, but that intrapallidal sulpiride induced Fos almost exclusively in PV-lacking pallidal neurons. No other intrapallidal drug-induced Fos showed similar population specificity. These results support evidence suggesting that GP DA can play a unique and critical role in modulating pallidal neuron function, and that the cessation of pallidal dopamine transmission can activate gene expression within the pallidal neuron subpopulation that maintains extensive axonal projections to caudate-putamen.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576184     DOI: 10.1016/s0006-8993(02)04060-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  Differential regulation of MeCP2 phosphorylation in the CNS by dopamine and serotonin.

Authors:  Ashley N Hutchinson; Jie V Deng; Dipendra K Aryal; William C Wetsel; Anne E West
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Opposite effects of stimulant and antipsychotic drugs on striatal fast-spiking interneurons.

Authors:  Alexander B Wiltschko; Jeffrey R Pettibone; Joshua D Berke
Journal:  Neuropsychopharmacology       Date:  2010-01-20       Impact factor: 7.853

3.  Nurr1 blocks the mitogenic effect of FGF-2 and EGF, inducing olfactory bulb neural stem cells to adopt dopaminergic and dopaminergic-GABAergic neuronal phenotypes.

Authors:  Eva Vergaño-Vera; Eva Díaz-Guerra; Eva Rodríguez-Traver; Héctor R Méndez-Gómez; Óscar Solís; Jaime Pignatelli; James Pickel; Sang-Hun Lee; Rosario Moratalla; Carlos Vicario-Abejón
Journal:  Dev Neurobiol       Date:  2014-12-10       Impact factor: 3.964

4.  Extrastriatal dopaminergic circuits of the Basal Ganglia.

Authors:  Karen S Rommelfanger; Thomas Wichmann
Journal:  Front Neuroanat       Date:  2010-10-27       Impact factor: 3.856

5.  Functional properties of striatal fast-spiking interneurons.

Authors:  Joshua D Berke
Journal:  Front Syst Neurosci       Date:  2011-06-20

6.  Dopaminergic control of the globus pallidus through activation of D2 receptors and its impact on the electrical activity of subthalamic nucleus and substantia nigra reticulata neurons.

Authors:  Omar Mamad; Claire Delaville; Wail Benjelloun; Abdelhamid Benazzouz
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

7.  Involvement of Basal Ganglia network in motor disabilities induced by typical antipsychotics.

Authors:  Jonathan Chetrit; Bérangère Ballion; Steeve Laquitaine; Pauline Belujon; Stéphanie Morin; Anne Taupignon; Bernard Bioulac; Christian E Gross; Abdelhamid Benazzouz
Journal:  PLoS One       Date:  2009-07-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.